The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: Role in tumor cell glycolysis and the Warburg effect
Open accessAbstract
Cancer cells maintain a high glycolytic rate even in the presence of oxygen, a phenomenon first described over 70 years ago and known historically as the Warburg effect. Fructose 2,6-bisphosphate is a powerful allosteric regulator of glycolysis that acts to stimulate the activity of 6-phosphofructo-1-kinase (PFK-1), the most important control point in mammalian glycolysis. The steady state concentration of fructose 2,6-bisphosphate in turn depends on the activity of the enzyme 6-phosphofructo-2-kinase (PFK-2)/fructose-2,6-bisphosphatase, which is expressed in several tissue-specific isoforms. We report herein the identification of a gene product for this enzyme that is induced by proinflammatory stimuli and which is distinguished by the presence of multiple copies of the AUUUA mRNA instability motif in its 3′-untranslated end. This inducible gene for PFK-2 is expressed constitutively in several human cancer cell lines and was found to be required for tumor cell growth in vitro and in vivo . Inhibition of inducible PFK-2 protein expression decreased the intracellular level of 5-phosphoribosyl-1-pyrophosphate, a product of the pentose phosphate pathway and an important precursor for nucleic acid biosynthesis. These studies identify a regulatory isoenzyme that may be essential for tumor growth and provide an explanation for long-standing observations concerning the apparent coupling of enhanced glycolysis and cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Shaw, G., & Kamen, R. (1986) · Cell · doi:10.1016/0092-8674(86)90341-7 · Cited by 4,012
Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Shimer, S., & Cerami, A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.6.1670 · Cited by 1,516
PRIMARY RESPONSE GENES INDUCED BY GROWTH FACTORS AND TUMOR PROMOTERS
Herschman, H. R. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001433 · Cited by 1,079
Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues
Hue, L., & Rider, M. H. (1987) · Biochemical Journal · doi:10.1042/bj2450313 · Cited by 422
Enzymology of Cancer Cells: (Second of Two Parts)
Weber, G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703102961005 · Cited by 416
Control of Messenger RNA Stability
(1993) · Elsevier eBooks · doi:10.1016/c2009-0-03269-3 · Cited by 379
Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors.
Van Schaftingen, E., Jett, M. F., Hue, L., & Hers, H. G. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3483 · Cited by 246
Piechaczyk, M., Yang, J.-Q., Blanchard, J.-M., Jeanteur, P., & Marcu, K. B. (1985) · Cell · doi:10.1016/0092-8674(85)90116-3 · Cited by 220
Truncation of exon 1 from the c-myc gene results in prolonged c-myc mRNa stability.
Rabbitts, P. H., Forster, A., Stinson, M. A., & Rabbitts, T. H. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04141.x · Cited by 165
Cited by
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
“Finally, one of the hallmark of cancer cells is an increased glycolytic rate (Warburg, 1956), which is frequently accompanied by elevated levels of Fru-2,6-P2 ( Chesney et al., 1999; Nissler et al.,”
BackgroundInfluentialMetabolic reprogramming in macrophages and dendritic cells in innate immunity
Kelly, B., & O'Neill, L. A. (2015) · Cell Research · doi:10.1038/cr.2015.68 · Cited by 1,876
Role of PFKFB3-Driven Glycolysis in Vessel Sprouting
De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B. W., Cantelmo, A. R., Quaegebeur, A., Ghesquière, B., Cauwenberghs, S., Eelen, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.037 · Cited by 1,551
Self-citationMultiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
Nickel essentiality, toxicity, and carcinogenicity
Denkhaus, E., & Salnikow, K. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00214-1 · Cited by 1,129
Management of cellular energy by the AMP‐activated protein kinase system
Hardie, D. G., Scott, J. W., Pan, D. A., & Hudson, E. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00560-x · Cited by 855
Marsin, A.-S., Bertrand†, L., Rider, M. H., Deprez, J., Beauloye, C., Vincent‡, M. F., Van den Berghe‡, G., Carling, D., & Hue, L. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00742-9 · Cited by 824
Kasprzak, K. S., Sunderman, F. W., & Salnikow, K. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.021 · Cited by 674
Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes
Altenberg, B., & Greulich, K. O. (2004) · Genomics · doi:10.1016/j.ygeno.2004.08.010 · Cited by 659
Causes and Consequences of Increased Glucose Metabolism of Cancers
Gillies, R. J., Robey, I., & Gatenby, R. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047258 · Cited by 623
Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis
Schoors, S., De Bock, K., Cantelmo, A. R., Georgiadou, M., Ghesquière, B., Cauwenberghs, S., Kuchnio, A., Wong, B. W., Quaegebeur, A., Goveia, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.008 · Cited by 529
Self-citationColell, A., Ricci, J.-E., Tait, S., Milasta, S., Maurer, U., Bouchier-Hayes, L., Fitzgerald, P., Guio-Carrion, A., Waterhouse, N. J., Li, C. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.045 · Cited by 516
Almeida, A., Moncada, S., & Bolaños, J. P. (2004) · Nature Cell Biology · doi:10.1038/ncb1080 · Cited by 480
RUBIO, M. P., GERAGHTY, K. M., WONG, B. H. C., WOOD, N. T., CAMPBELL, D. G., MORRICE, N., & MACKINTOSH, C. (2004) · Biochemical Journal · doi:10.1042/bj20031797 · Cited by 442
RIDER, M. H., BERTRAND, L., VERTOMMEN, D., MICHELS, P. A., ROUSSEAU, G. G., & HUE, L. (2004) · Biochemical Journal · doi:10.1042/bj20040752 · Cited by 440
Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M. A., Arumugam, S., Dean, W. L., Eaton, J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0482 · Cited by 432
Self-citationLactate: mirror and motor of tumor malignancy
Walenta, S., & Mueller-Klieser, W. F. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.004 · Cited by 428
Dynamics of the Cellular Metabolome during Human Cytomegalovirus Infection
Munger, J., Bajad, S. U., Coller, H. A., Shenk, T., & Rabinowitz, J. D. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020132 · Cited by 417
AMP-Activated Protein Kinase as a Drug Target
Hardie, D. G. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105304 · Cited by 407
Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer
Yalcin, A., Telang, S., Clem, B., & Chesney, J. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.003 · Cited by 405
Self-citationBakheet, T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.246 · Cited by 398
Marsin, A.-S., Bouzin, C., Bertrand, L., & Hue, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205213200 · Cited by 379
Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V., & Caro, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110978200 · Cited by 370
The molecular determinants of de novo nucleotide biosynthesis in cancer cells
Tong, X., Zhao, F., & Thompson, C. B. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.002 · Cited by 351
Mitochondrial Pathology and Glycolytic Shift during Proximal Tubule Atrophy after Ischemic AKI
Lan, R., Geng, H., Singha, P. K., Saikumar, P., Bottinger, E. P., Weinberg, J. M., & Venkatachalam, M. A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020177 · Cited by 353
Yang, Z., Fujii, H., Mohan, S. V., Goronzy, J. J., & Weyand, C. M. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130252 · Cited by 334
“Rapidly proliferating cells, including tumors, have the inducible isoform of 6phosphofructo2kinase/fructose2,6bisphosphatase 3 (PFKFB3), which allows them to promptly attend to height ened energy demands (Chesney et al., 1999).”
BackgroundChen, J.-Q., & Russo, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.004 · Cited by 327
Control of Glycolysis through Regulation of PFK1: Old Friends and Recent Additions
Mor, I., Cheung, E. C., & Vousden, K. H. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010868 · Cited by 316
New aspects of the Warburg effect in cancer cell biology
Bensinger, S. J., & Christofk, H. R. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.02.003 · Cited by 307
Dysregulated metabolism contributes to oncogenesis
Hirschey, M. D., DeBerardinis, R. J., Diehl, A. M. E., Drew, J. E., Frezza, C., Green, M. F., Jones, L. W., Ko, Y. H., Le, A., Lea, M. A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.10.002 · Cited by 305
Shi, L., Pan, H., Liu, Z., Xie, J., & Han, W. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.44 · Cited by 292
Emerging Roles of Energy Metabolism in Ferroptosis Regulation of Tumor Cells
Yao, X., Li, W., Fang, D., Xiao, C., Wu, X., Li, M., & Luo, Z. (2021) · Advanced Science · doi:10.1002/advs.202100997 · Cited by 282
Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression
Fang, J. S., Gillies, R. D., & Gatenby, R. A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.011 · Cited by 277
Obach, M., Navarro-Sabaté, À., Caro, J., Kong, X., Duran, J., Gómez, M., Perales, J. C., Ventura, F., Rosa, J. L., & Bartrons, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406096200 · Cited by 276
Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer
Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0097 · Cited by 276
Self-citationRos, S., & Schulze, A. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-8 · Cited by 269
Pathania, D., Millard, M., & Neamati, N. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.010 · Cited by 263
Flaster, H., Bernhagen, J., Calandra, T., & Bucala, R. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0065 · Cited by 260
Self-citationHypoxia, glucose metabolism and the Warburg’s effect
Bartrons, R., & Caro, J. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9080-3 · Cited by 260
Minchenko, O., Opentanova, I., & Caro, J. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01179-7 · Cited by 236
RNA-binding proteins control gene expression and cell fate in the immune system
Turner, M., & Díaz-Muñoz, M. D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0028-4 · Cited by 209
Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements
Khabar, K. S. A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0383-x · Cited by 157
Ruiz-García, A., Monsalve, E., Novellasdemunt, L., Navarro-Sabaté, À., Manzano, A., Rivero, S., Castrillo, A., Casado, M., Laborda, J., Bartrons, R., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190298 · Cited by 95
Cerebral gluconeogenesis and diseases
Yip, J., Geng, X., Shen, J., & Ding, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00521 · Cited by 89
The unfolded protein response and cancer: A brighter future unfolding?
Scriven, P., Brown, N. J., Pockley, A. G., & Wyld, L. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0150-5 · Cited by 67
Metadata
- Authors
- Chesney, J., Mitchell, R., Benigni, F., Bacher, M., Spiegel, L., Al-Abed, Y., Han, J. H., Metz, C., & Bucala, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-03-16
- Volume
- 96
- Issue
- 6
- Pages
- 3047-3052
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2079854321
- Cited by
- 287
- References
- 22
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.